ConductScience.org, home

Paper9819829

Optimal flexible designs in phase II clinical trials.

Chen TT and 1 other. Stat Med, 1998. Cited by 100 papers, by iCite.

Cite this record

ConductScience Library. Optimal flexible designs in phase II clinical trials. Papers, record 9819829. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9819829

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Optimal flexible designs in phase II clinical trials.
PubMed
Journal
Stat Med
PubMed
Year
1998
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
100
iCite
Relative citation ratio, by iCite
2.25
iCite
Revised in PubMed
2019-08-31
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chen TTT T
2Ng THT H

Source PubMed

Download CSV of authors

Topics3

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Clinical Trials, Phase II as TopicMajor topic
Research Design
Statistics as Topic

Cited by54

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 100 citations.

PMIDTitleJournalYearIn PapersSource
38603953Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.Gynecol Oncol2024https://conductscience.org/library/papers/38603953PubMed
38574312Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279.J Clin Oncol2024https://conductscience.org/library/papers/38574312PubMed
38473419The Potential Influence of Residual or Recurrent Disease on Bevacizumab Treatment Efficacy in Ovarian Cancer: Current Evidence and Future Perspectives.Cancers (Basel)2024https://conductscience.org/library/papers/38473419PubMed
37418832A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.Gynecol Oncol2023https://conductscience.org/library/papers/37418832PubMed
35868503Inefficiency of two-stage designs in phase II oncology clinical trials with high proportion of inevaluable patients.Contemp Clin Trials2022https://conductscience.org/library/papers/35868503PubMed
34875107A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.Cancer2022https://conductscience.org/library/papers/34875107PubMed
33717225Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trial.Ther Adv Med Oncol2021https://conductscience.org/library/papers/33717225PubMed
31934607
Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008).
Gynecol Oncol Rep2020https://conductscience.org/library/papers/31934607PubMed
31924334Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).Gynecol Oncol2020https://conductscience.org/library/papers/31924334PubMed
30309721
A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.
Gynecol Oncol2018https://conductscience.org/library/papers/30309721PubMed
28774461Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer.Gynecol Oncol2017https://conductscience.org/library/papers/28774461PubMed
28303530
A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer.
Invest New Drugs2017https://conductscience.org/library/papers/28303530PubMed
28029447A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study.Gynecol Oncol2017https://conductscience.org/library/papers/28029447PubMed
27500329Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia.Obstet Gynecol2016https://conductscience.org/library/papers/27500329PubMed
26975418A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer.Clin Colorectal Cancer2016https://conductscience.org/library/papers/26975418PubMed
26616224A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study.Gynecol Oncol2016https://conductscience.org/library/papers/26616224PubMed
26368810A Rescue Strategy for Handling Unevaluable Patients in Simon's Two Stage Design.PLoS One2015https://conductscience.org/library/papers/26368810PubMed
26368744Nine-year change in statistical design, profile, and success rates of Phase II oncology trials.J Biopharm Stat2016https://conductscience.org/library/papers/26368744PubMed
26048655Statistical inference for extended or shortened phase II studies based on Simon's two-stage designs.BMC Med Res Methodol2015https://conductscience.org/library/papers/26048655PubMed
25818403
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol2015https://conductscience.org/library/papers/25818403PubMed

See all 54 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9819829

GET https://conductscience.org/api/papers/v1/9819829/cited_by?page=2